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Introduction: We report the case of a patient with Churg-Strauss syndrome with eighth cranial nerve palsy.
Vestibulocochlear nerve palsy is extremely rare in Churg-Strauss syndrome. To the best of our knowledge, only one
case of complicated neuropathy of the eighth cranial nerve has been described in a previous report presenting an
aggregate calculation, but no differentiation between polyarteritis nodosa and Churg-Strauss syndrome was made.
High-dose immunoglobulin was administered to our patient, and her neuropathy of the eighth cranial nerve
showed improvement.
Case presentation: At the age of 46, a Japanese woman developed Churg-Strauss syndrome that later became
stable with low-dose prednisolone treatment. At the age of 52, she developed sudden difficulty of hearing in her
left ear, persistent severe rotary vertigo, and mononeuritis multiplex. At admission, bilateral perceptive deafness of
about 80dB and eosinophilia of 4123/μL in peripheral blood were found. A diagnosis of cranial neuropathy of the
eighth cranial nerve associated with exacerbated Churg-Strauss syndrome was made. Although high doses of
steroid therapy alleviated the inflammatory symptoms and markers, the vertigo and bilateral hearing loss remained.
Addition of a high-dose immunoglobulin finally resulted in marked alleviation of the symptoms associated with
neuropathy of the eighth cranial nerve.
Conclusions: A high dose of immunoglobulin therapy shows favorable effects in neuropathy of the eighth cranial
nerve, but no reports regarding its efficacy in cranial neuropathy have been published.
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Churg-Strauss syndrome (CSS), also known as allergic
granulomatous angiitis, is a syndrome consisting of angii-
tis in the systemic small vessels, bronchial asthma, eo-
sinophilia, fever, and vasculitis of various organ systems
[1]. Mononeuritis multiplex is seen in 36.1% to 71.8% of
cases of CSS [2-5]. However, cranial neuropathy is rare in
CSS, and neuropathy of the eighth cranial nerve is ex-
tremely rare. Although a case of complicated neuropathy* Correspondence: ozakiy@takii.kmu.ac.jp
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port presenting an aggregate calculation without differen-
tiating between polyarteritis nodosa and CSS [6], no cases
that could be definitively diagnosed as CSS have been
reported.
Intravenous infusion therapy with high doses of im-
munoglobulin (intravenous immunoglobulin, or IVIg)
has been shown to be efficacious in Kawasaki disease
and idiopathic thrombocytopenia. Also, IVIg was
reported to be effective in cases of new-onset CSS [7]
and in pregnant women with CSS in whom immunosup-
pressants cannot be administered [8]. In Japan, IVIg has
been approved for neuropathy of the peripheral nervestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Laboratory findings of the patient on admission
Parameter Value Normal range
White blood cell count, ×102/μL 133 35-85
Neutrophil, percentage 63.0 42.0-77.0
Basophil, percentage 0.5 0.1-2.0
Eosinophil, percentage 31.0 0.5-6.0
Lymphocyte, percentage 3.5 18.0-49
Monocyte, percentage 2.0 3.0-9.0
Red blood cell count, ×104/μL 413 370-510
Hemoglobin, g/dL 14.5 11.3-15.4
Hematocrit, percentage 41.9 34 - 46
Platelet, 104/μL 18.1 14 - 34
Glucose, mg/dL 98 60-100
Hemoglobin A1c, percentage 5.7 4.0-6.0
Sodium, mEq/L 144 138-146
Potassium, mEq/L 3.7 3.5-5.0
Chloride, mEq/L 102 100-110
Blood urea nitrogen, mg/dL 8 8-20
Creatinine, mg/dL 0.55 0.4-0.8
Uric acid, mg/dL 3.1 2.5-5.5
Calcium, mg/dL 8.8 8.5-10.3
Total protein, g/dL 6.2 6.5-8.2
Albumin, g/dL 3.9 3.8-5.0
Aspartate aminotransferase, U/L 17 13-35
Alanine aminotransferase, U/L 5 5-35
Total bilirubin, mg/dL 0.6 0.2-1.2
Alkaline phosphatase , U/L 115 107-340
γ-Glutamyl transpeptidase, U/L 36 8-45
Lactate dehydrogenase, U/L 226 112-230
Creatine kinase, U/L 36 45-165
Amylase, U/L 61 37-125
C-reactive protein, mg/dL 6.408 <0.3
IgG, mg/dL 883 870-1700
IgA, mg/dL 112 110-410
IgM, mg/dL 82 46-260
IgE, IU/mL 421 <320
MPO-ANCA, EU 226 <20
PR3-ANCA, U/mL 0 <3.5
Rheumatoid factor, IU/mL 5 <20
Anti-nuclear antibody ×20 <×40
Ig: immunoglobulin; MPO-ANCA: myeloperoxidase anti-neutorophil
cytoplasmic antibody; PR3-ANCA: proteinase 3 anti-neutorophil cytoplasmic
antibody.
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scheme. Although IVIg shows favorable effects in neur-
opathy of the peripheral nerves, no reports regarding its
efficacy in cranial neuropathy have been published. Here,
we report a case of CSS complicated by neuropathy of
the eighth cranial nerve in which IVIg was effective.
Case presentation
A 35-year-old Japanese woman with no notable medical
or family histories developed bronchial asthma. Treat-
ment was initiated, and the course of bronchial asthma
had been favorable. After 11 years, rotary vertigo, diffi-
culty of hearing in the right ear, and palsies of the left
lower extremity and right forearm occurred. A diagnosis
of CSS was made on the basis of bronchial asthma, neur-
opathy of the peroneal nerve and ulnar nerve, findings of
angiitis by biopsy of the left sural nerve, increased eosino-
phil counts, and positivity for myeloperoxidase anti-
neutrophil cytoplasmic antibody (MPO-ANCA). The
pathological conditions were alleviated by prednisolone
(PSL) treatment with a tapering schedule from a dose of
1mg/kg and methyl-prednisolone pulse therapy (mPSL).
Three years later, owing to another increase in MPO-
ANCA and exacerbation of peripheral nerve neuropathy
during PSL treatment at a dose of 10mg/day, mPSL pulse
therapy was administered again and the dose of PSL was
increased to 50mg/day (1mg/kg). However, because the
neuropathy was not alleviated, intravenous cyclophospha-
mide (IVCY) pulse therapy (750mg/body) was adminis-
tered six times every four weeks. The IVCY therapy
stabilized our patient’s condition. Subsequently, the dose
of PSL was decreased to 10mg/dL gradually.
More than three years later (when our patient was
52 years old), she was hospitalized again because of the
recurrence of bilateral hearing difficulty and rotary ver-
tigo. At admission, physical findings included a body
temperature of 36.2°C, a blood pressure of 132/74mmHg,
a pulse of 66 beats per minute, and a respiratory rate of
18 per minute. No abnormal cardiac sounds were noted,
and mild wheezing sounds were present in the lung field.
Spontaneous leftward horizontally rotary mixed nystag-
mus was present, and owing to strong vertigo our patient
had difficulty being in a sitting position. A hearing test
revealed average hearing thresholds of 86.3dB in the right
ear and 78.8dB in the left ear, which indicated severe per-
ceptive deafness (sensorineural hearing impairment). She
did not have tinnitus or recruitment phenomenon.
Neurological findings included neuropathies of the right
ulnar, left peroneal, and right tibial nerves, and left foot
drop. Chest radiography and head magnetic resonance
imaging did not show any abnormalities, and examination
findings included a leukocyte count of 13,300/μL, an eo-
sinophil count of 31.0% (4123/μL), a C-reactive protein
(CRP) level of 6.408mg/dL, and an MPO-ANCA of226EU (Table 1). The results of serum cytokine measure-
ments by the cytometric bead array method were as fol-
lows: interleukin-4 (IL-4) of 3.3pg/mL (normal is less
than 1.4), IL-5 of 11pg/mL (normal is less than 1.1), IL-6
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(normal is less than 0.13), IL-13 of 7.4pg/mL (normal is
less than 0.6), and interferon-gamma (IFNγ) of 0.1pg/mL
(normal is less than 1.8).
The diagnosis was neuropathy of the eighth cranial
nerve associated with exacerbation of allergic granu-
lomatous angiitis, and mPSL pulse therapy and subse-
quent oral PSL at a dose of 55mg/day (1mg/kg per day)
were begun. This treatment resulted in gradual alleviation
of bronchial asthma, eosinophilia, CRP level, and mono-
neuritis multiplex but not of the foot drop. Also, the hear-
ing difficulty and vertigo were not alleviated. Although
reinforced treatment by IVCY was planned initially, our
patient refused because of the severe nausea that occurred
in the previous IVCY treatment. Therefore, IVIg (400mg/kg
per day for five days) was combined from day 14. From
around day 20, the hearing ability and foot drop began to
improve gradually. On day 42, a hearing test revealed
average hearing thresholds of 70.0 and 61.7dB in the right
and left ears, respectively, and the vertigo had disappeared.
After our patient was discharged from the hospital, the
dose of PSL was decreased to 10mg/day and her condition
is currently stable.
Discussion
Because the vertigo continued for a long period of time
and recruitment phenomenon and tinnitus were not
present, we ruled out atypical sudden deafness in our
patient. Since auditory brain-stem response was not per-
formed, the cause of her hearing loss was not identified.
Her vertigo and deafness were likely the results of CSS
exacerbation or late flare-up, which was evidenced by
rising titers of MPO-ANCA and inflammatory markers.
Thus, the presumptive diagnosis of CSS-associated cra-
nial neuropathy involving the eighth cranial nerve was
made, and the condition subsequently resolved with im-
munoglobulin therapy.
Conclusions
CSS accompanying cranial neuropathy is relatively rare.
Guillevin et al. [9] reported that only four out of 96 CSS
cases were complicated by cranial neuropathy. In the
present case, the perceptive deafness with vertigo corre-
sponded to pathological conditions of CSS, such as
increased MPO-ANCA and some inflammatory markers
and exacerbated neuropathy of the peripheral nerves.
With regard to serum cytokine concentrations in CSS,
increases in Th2 cytokines IL-4 [10], IL-5 [11], IL-10
[12], and IL-13 [10,13] have been reported, although
there are reports showing no apparent increases in IL-4
[13], IL-5, and IL-10 [10]. In the present case, increases
in serum level of inflammatory cytokine IL-6 and IL-4,
IL-5, IL-10, and IL-13, but not Th1 cytokine IFNγ, were
found.As a disease complicated by angiitis and perceptive deaf-
ness, Cogan syndrome in aortitis syndrome is well known.
However, the pathogenesis of perceptive deafness with
Cogan syndrome remains unclear. Meanwhile, the etiology
of neuropathies in CSS has been suggested to be involved
in damage by feeding vessels of the peripheral nerves.
It is speculated that the effect of IVIg is due to the
blockade of Fc receptors, adjustment of complement ac-
tivities with idiotype network [14], or inhibition of dam-
age to myelin or axons as an antigen [15]. In the present
case, as for mononeuritis multiplex of the sensory nerves,
mPSL pulse therapy was effective. The foot drop as a
neuropathy of the motor nerve and the neuropathy of the
eighth cranial nerve were resistant to the mPSL pulse
therapy but were alleviated after administration of IVIg.
We inferred that the effects of steroids were enhanced
through some active mechanisms of IVIg as speculated
above. Given our present case, IVIg could possibly be a
useful treatment for cranial neuropathy associated with
CSS and should be taken into consideration for cases in
which the effects of mPSL pulse therapy are insufficient
or administration of immunosuppressants is difficult.
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